Cargando…

Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions

For patients with advanced non–small cell lung cancer, genomic profiling of tumors to identify potentially targetable alterations and thereby inform treatment selection is now part of standard care. While molecular analyses are primarily focused on actionable biomarkers associated with regulatory ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbst, Roy S., Aisner, Dara L., Sonett, Joshua R., Turk, Andrew T., Weintraub, Joshua L., Lindeman, Neal I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859651/
https://www.ncbi.nlm.nih.gov/pubmed/33553195
http://dx.doi.org/10.3389/fmed.2020.562480
_version_ 1783646780960800768
author Herbst, Roy S.
Aisner, Dara L.
Sonett, Joshua R.
Turk, Andrew T.
Weintraub, Joshua L.
Lindeman, Neal I.
author_facet Herbst, Roy S.
Aisner, Dara L.
Sonett, Joshua R.
Turk, Andrew T.
Weintraub, Joshua L.
Lindeman, Neal I.
author_sort Herbst, Roy S.
collection PubMed
description For patients with advanced non–small cell lung cancer, genomic profiling of tumors to identify potentially targetable alterations and thereby inform treatment selection is now part of standard care. While molecular analyses are primarily focused on actionable biomarkers associated with regulatory agency-approved therapies, there are a number of emerging biomarkers linked to investigational agents in advanced stages of clinical development will become approved agents. A particularly timely example is the reported data and US Food and Drug Administration approval of highly specific small molecule inhibitors of the proto-oncogene tyrosine-protein kinase receptor RET indicate that testing for tumor RET gene fusions in patients with NSCLC has become clinically important. As the number of biomarkers to be tested in NSCLC grows, it becomes increasingly important to optimize and prioritize the use of biopsy tissue, in order to both continue to allow accurate histopathological diagnosis and also to support concurrent genomic profiling to identify perhaps relatively uncommon genetic events. In order to provide practical expert consensus guidance to optimize processes facilitating genomic testing in NSCLC and to overcome barriers to access and implementation, a multidisciplinary advisory board was held in New York, on January 30, 2019. The panel comprised physicians involved in sample procurement (interventional radiologists and a thoracic surgeon), surgical pathologists specializing in the lung, molecular pathologists, and thoracic oncologists. Particular consideration was given to the key barriers faced by these experts in establishing institutional genomic screening programs for NSCLC. Potential solutions have been devised in the form of consensus opinions that might be used to help resolve such issues.
format Online
Article
Text
id pubmed-7859651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78596512021-02-05 Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions Herbst, Roy S. Aisner, Dara L. Sonett, Joshua R. Turk, Andrew T. Weintraub, Joshua L. Lindeman, Neal I. Front Med (Lausanne) Medicine For patients with advanced non–small cell lung cancer, genomic profiling of tumors to identify potentially targetable alterations and thereby inform treatment selection is now part of standard care. While molecular analyses are primarily focused on actionable biomarkers associated with regulatory agency-approved therapies, there are a number of emerging biomarkers linked to investigational agents in advanced stages of clinical development will become approved agents. A particularly timely example is the reported data and US Food and Drug Administration approval of highly specific small molecule inhibitors of the proto-oncogene tyrosine-protein kinase receptor RET indicate that testing for tumor RET gene fusions in patients with NSCLC has become clinically important. As the number of biomarkers to be tested in NSCLC grows, it becomes increasingly important to optimize and prioritize the use of biopsy tissue, in order to both continue to allow accurate histopathological diagnosis and also to support concurrent genomic profiling to identify perhaps relatively uncommon genetic events. In order to provide practical expert consensus guidance to optimize processes facilitating genomic testing in NSCLC and to overcome barriers to access and implementation, a multidisciplinary advisory board was held in New York, on January 30, 2019. The panel comprised physicians involved in sample procurement (interventional radiologists and a thoracic surgeon), surgical pathologists specializing in the lung, molecular pathologists, and thoracic oncologists. Particular consideration was given to the key barriers faced by these experts in establishing institutional genomic screening programs for NSCLC. Potential solutions have been devised in the form of consensus opinions that might be used to help resolve such issues. Frontiers Media S.A. 2021-01-21 /pmc/articles/PMC7859651/ /pubmed/33553195 http://dx.doi.org/10.3389/fmed.2020.562480 Text en Copyright © 2021 Herbst, Aisner, Sonett, Turk, Weintraub and Lindeman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Herbst, Roy S.
Aisner, Dara L.
Sonett, Joshua R.
Turk, Andrew T.
Weintraub, Joshua L.
Lindeman, Neal I.
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title_full Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title_fullStr Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title_full_unstemmed Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title_short Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
title_sort practical considerations relating to routine clinical biomarker testing for non–small cell lung cancer: focus on testing for ret fusions
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859651/
https://www.ncbi.nlm.nih.gov/pubmed/33553195
http://dx.doi.org/10.3389/fmed.2020.562480
work_keys_str_mv AT herbstroys practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions
AT aisnerdaral practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions
AT sonettjoshuar practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions
AT turkandrewt practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions
AT weintraubjoshual practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions
AT lindemanneali practicalconsiderationsrelatingtoroutineclinicalbiomarkertestingfornonsmallcelllungcancerfocusontestingforretfusions